References
- Davis A E, 3rd. The pathophysiology of hereditary angioedema. Clin Immunol 2005; 114: 3–9
- Frank M M, Gelfand J A, Atkinson J P. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976; 84: 580–93
- Fay A, Abinun M. Current management of hereditary angio-oedema (C′1 esterase inhibitor deficiency). J Clin Pathol 2002; 55: 266–70
- Zuraw B L, Herschbach J. Detection of C1 inhibitor mutations in patients with hereditary angioedema. J Allergy Clin Immunol 2000; 105: 541–6
- Bork K, Barnstedt S E, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356: 213–7
- Binkley K E, Davis A, 3rd. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000; 106: 546–50
- Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343: 1286–9
- Cichon S, Martin L, Hennies H C, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098–104
- Farsetti A, Misiti S, Citarella F, et al. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 1995; 136: 5076–83